Please login to the form below

Not currently logged in
Email:
Password:

Novartis' Reclast for osteoporosis approved by FDA

Swiss pharmaceutical company Novartis has won FDA approval for its osteoposis drug, Reclast (zoledronic acid), for the treatment of women with postmenopausal osteoporosis.

Swiss pharmaceutical company Novartis has won FDA approval for its osteoposis drug, Reclast (zoledronic acid), for the treatment of women with postmenopausal osteoporosis.

Novartis added that the European Commission (EC) is also expected to give its approval for Reclast in Q4 2007, following the positive opinion of the Committee for Medicinal Products. Reclast is already sold in the US and the EU as a treatment for Paget's disease.

In a clinical study involving more than 7,700 women, Reclast reduced the risk of spine fracture by 70 per cent and hip fracture by 41 per cent, Novartis said in a statement. The drug is administered as a once yearly intravenous injection.

Reclast is already in clinical studies to test Reclast's efficacy in the treatment of male osteoporosis.

According to a Datamonitor report, the osteoporosis market is due for a major upheaval when market leader Fosamax (alendronate) loses its US patent. New market entrants provide further complexity to the competitive landscape but will also drive market growth over the next ten years.

Eli Lilly has launched two osteoporosis drugs, Evista (raloxifene) and Forteo (teriparatide). In 2006, Evista generated sales of USD 739, while Forteo generated revenue of USD 574m.

21st August 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
wearable health tech
A cultural shift in clinical research
Research organisations across the board are experimenting with new technologies...

Infographics